Severe asthma remains uncontrolled despite high-dose inhalers and optimal treatment.
Precision medicine uses biomarkers (eosinophils, FeNO, IgE) to identify the asthma type and select targeted therapy.
Biologics such as Omalizumab, Mepolizumab, Benralizumab, and Dupilumab target specific inflammatory pathways, reducing exacerbations and improving asthma control.
Key message: "The right biologic for the right patient at the right time."
